Antibodies to tau and methods of treatment therewith
AssigneeEli Lilly and Company
InventorsMansuo Lu Hayashi, Jirong Lu, David Driver, Alberto Alvarado
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.
Claims6
A method of treating Alzheimer's disease, Progressive Supranuclear Palsy or Pick's disease comprising administering to a patient in need thereof an effective amount of a monoclonal antibody that binds human tau, wherein said monoclonal antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein the amino acid sequence of LCDR1 is set forth by SEQ ID NO:
- 3, the amino acid sequence of LCDR2 is set forth by SEQ ID NO:
- 4, the amino acid sequence of LCDR3 is set forth by SEQ ID NO:
- 5, the amino acid sequence of HCDR1 is set forth by SEQ ID NO:
- 6, the amino acid sequence of HCDR2 is set forth by SEQ ID NO:
- 7, and the amino acid sequence of HCDR3 is set forth by SEQ ID NO:
- 8.
A method of treating Alzheimer's disease, Progressive Supranuclear Palsy or Pick's disease comprising administering to a patient in need thereof a pharmaceutical composition comprising a monoclonal antibody that binds human tau, wherein said monoclonal antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein the amino acid sequence of LCDR1 is set forth by SEQ ID NO:
- 3, the amino acid sequence of LCDR2 is set forth by SEQ ID NO:
- 4, the amino acid sequence of LCDR3 is set forth by SEQ ID NO:
- 5, the amino acid sequence of HCDR1 is set forth by SEQ ID NO:
- 6, the amino acid sequence of HCDR2 is set forth by SEQ ID NO:
- 7, and the amino acid sequence of HCDR3 is set forth by SEQ ID NO:
- 8, and one or more pharmaceutically acceptable carriers, diluents or excipients.
Dependencies are inferred from the claim text.